Poly (ADP-ribose) glycohydrolase (PARG), which was discovered during studies on DNA damage study and in inflammation research, is an attractive target protein in current cancer research. The enzymatic hydrolysis of poly (ADP-ribose) (PAR) has not been clarified in the regulation of cancer. The purpose of this study was to understand the relationship between PARG and the adhesion of colorectal carcinoma CT26 cells to platelets. PARG was silenced by short hairpin RNA (shRNA) transfection in CT26 cells. A fluorescence method was used to identify adhesion of CT26 cells to platelets and the expression of poly (ADP-ribose) polymerase (PARP)-1, p-Akt, nuclear factor kappa-B (NF-kB), P-selectin and intercellular adhesion molecule-1 (ICAM-1) was analyzed by western blot in various treated groups and control groups. The results were as follows: (a) PARG silencing led to inhibition of adhesion of CT26 cells to platelets, whereas an inhibitor of p-Akt boosted adhesion of PARG-short hairpin RNA interference (shRNAi) CT26 cells to platelets; (b) a PARP-1 inhibitor depressed the expression of P-selectin and ICAM-1 in CT26 cells; (c) PARG silencing increased phosphorylation of Akt and decreased expression of PARP-1, NF-kB, ICAM-1 and P-selectin in CT26 cells; and (d) a p-Akt inhibitor intensified expression of NF-kB, ICAM-1 and P-selectin in PARG-shRNAi CT26 cells accordingly. These results showed the effectiveness of knockout of PARG in inhibiting adhesion of CT26 cells to platelets and its connection with the phosphatidylinositol 3 kinase/Akt pathway.
INTRODUCTION
Poly (ADP-ribosyl)ation (PARsylation) regulates many cellular processes, including DNA repair, chromatin structure, mitosis and apoptosis. Poly (ADP-ribose) glycohydrolase (PARG) specifically catabolizes the ribose-ribose bonds of poly (ADP-ribose) (PAR) chains, while poly (ADP-ribose) polymerases (PARPs) synthesize PAR, in response to various stimuli. So far, the superfamily of PARPs has been studied extensively, while only two isoforms of PARGs have been documented in mice: PARG 110 is the major form of PARG, localizing in the nucleus and in the cytoplasm; the other isoform is PARG 60 , localizing in the cytosolic fraction. 1, 2 Recently, some scientists began to focus on role of PARG in tumors, Sun et al. 3 found that a PARG inhibitor sensitized ovarian carcinoma cells to cisplatin and Erdé lyi et al. 4 discovered dual role of PARG in regulation of cell death in A549 lung adenocarcinoma cell lines with oxidative damage. Although some researchers had begun to explore the interaction between nuclear PARP-1 and PARG, [5] [6] [7] their conclusions were in controversy. The cooperation of these two enzymes in tumor cells is particularly unclear. Frizzell et al. 7 found that PARP-1 and PARG have similar, rather than antagonistic, roles in regulating gene expression in MCF-7 human breast cancer cells. In addition, our previous study demonstrated that silencing PARG led to the inhibition of expression of PARP-1 in human colorectal cancer LoVo cells. 8 Adhesion of tumor cells to platelets is the key of formation of tumor emboli. Thus, the expression of adhesion molecules on the tumor cell membrane is the pivotal factor in adhesion. A previous study had indicated that two types of adhesion molecule, P-selectin and intercellular adhesion molecule-1 (ICAM-1), were detected on colorectal carcinoma cells. 9 Frenette et al. 10 showed that P-selectin glycoprotein ligand 1 (Psgl-1) was also expressed on platelets. Furthermore, Stone and Wagner 11 confirmed that smallcell lung cancer and neuroblastoma expressed P-selectin and that the molecule could connect tumor cells and platelets. On the other hand, ICAM-1, a type of single-surface glycoprotein, belongs to the immunoglobulin gene superfamily, which are capable of both homotypic binding and heterotypic adhesion. 12 Kim et al. 13 and Biggerstaff et al.
14 pointed out that ICAM-1 induced the adhesion of platelets to endothelial cells and melanoma cells. In addition, McCaffery and Berridge 15 discovered that leukocyte functional molecule-1 (LFA-1, the partner of ICAM-1) is expressed on mouse platelets. Therefore, ICAM-1 and P-selectin on CT26 tumor cells could be involved in adhesion of platelets to tumor cells by binding to ligands on the platelets.
Akt (protein kinase B) is a central signaling molecule in the phosphatidylinositol 3 kinase (PI3K) pathway. Activation of PI3K localizes Akt to the plasma membrane. Akt is activated by phosphorylation at Thr 308 and Ser
473
. The PI3K/Akt pathway is well known to regulate a large number of cell functions, including survival, proliferation, invasion and migration in several cancers of some adhesion molecules, including P-selectin and ICAM-1. 22, 23 Therefore, this pathway may be associated with adhesion of tumor cells.
Inhibition of PARP-1 has been shown to have protecting role by activating Akt in some inflammatory diseases. [24] [25] [26] As we previously demonstrated that silencing PARG led to the inhibition of expression of PARP-1 and activation of the PI3K/Akt pathway, sequentially inhibiting expression of NF-kB resulting in suppression of growth of human colon cancer cells. 8 Based on the theories above, in this study, we have tested our hypothesis that silencing PARG could inhibit adhesion of CT26 cells to platelets by depressing P-selectin and ICAM-1 via the PI3K/Akt pathway and have found the potential mechanism as well as correlation of PARP and PARG in this pathological process.
MATERIALS AND METHODS

Cells and culture conditions
The CT26 cell line was grown in an incubator under standard conditions: 37 1C, 5% CO 2 with RPMI 1640 medium (Gibco, Grand Island, NY, USA) containing 10% fetal calf serum and penicillin/streptomycin (Sigma Chemical, St Louis, MO, USA).
Mice
We purchased 8-to-10-week-old male BALB/c mice from Animal Center of Chongqing Medical University, Chongqing, China. All animals were maintained in the specific pathogen-free facility. The care and handling of the animals was carried out in compliance with the Chinese Science Institutes of Health Guide (Animal Welfare Act) and was reviewed and approved by the Institutional Animal Care and Use Committee of Chongqing Medical University.
The groups in our study Untreated CT26 cells served as the blank control group; CT26 cells transfected with PARG-shRNAi inserted by lentivirus served as the PARGshRNAi group; CT26 cells treated with empty viral particles served as the 'empty viral particles control group'. Meanwhile, in cell-adhesion experiments, CT26 cells treated with EDTA served as a positive control group. In western blot, CT26 cells treated with 5-aminoisoquinolinone (a novel and potent inhibitor of PARP activity) served as the 5-aminoisoquinolinone group. Moreover, for experiments on how PARG influenced the cytokines through the p-Akt signaling pathway, CT26 cells treated with LY294002 (an inhibitor of p-Akt) and PARG-shRNAi inserted by lentivirus, served as the PARG-shRNAi þ LY group.
Cells transfection
Transfection was carried out with a lentiviral-based short hairpin RNA (shRNA) vector targeting PARG gene and with empty viral particles; the procedure was carried out according to the manufacturer's instructions (Sigma). In all, 1.6 Â 10 4 CT26 cells in RPMI 1640 medium were added to each well in a 96-well plate and were incubated for 1 day at 37 1C in a humidified incubator in an atmosphere containing 5% CO 2. The medium was removed from the wells. To each well, 200 ml fresh medium with hexadimethrine bromide (Sigma Chemical) to a final concentration of 8 mg ml was added. Then, 10 ml viral particles were added to each well; for each lentivirus construct triplicate wells were used. After the cells had been incubated for 2 days at 37 1C, the medium was removed and was replaced with 200 ml fresh medium containing puromycin (Sigma Chemical) to a final concentration of 5 mg ml every 3-4 days. This step was repeated four times for 12 days, until resistant colonies were identified. The cells for each group were harvested. The proteins were tested by western blot and the level of expression of the PARG gene was assayed by quantitative PCR at the same time.
Real-time PCR
The PARG gene template code was accessed at NCBI and the software (Primer premier 5.0, Palo Alto, CA, USA) was used to design the oligonucleotide primers as follow: PARG:
0 -GGTGAACGCTGTGAACGG-3 0 (sense) and 5 0 -TGTTAGTGGGGTCTCGCTCCT-3 0 (antisense). They were synthesized by SBS (Beijing, China). Total RNA was extracted by RNAiso Plus (Takara, Dalian, China). Then, a gel electrophoresis test showed that the gene had not been degraded. Reverse-transcription was carried out to obtain complementary DNA, according to the steps provided by PrimeScript RT reagent Kit protocol (Takara). Quantitative PCR was carried out with the 25 ml reaction system and amplifications were done with the following reaction procedures: 39 cycles of denturation at 95 1C for 30 s, followed with 1 cycle at 95 1C for 5 s and 1 cycle at 60 1C for 30 s.
Cell-platelet adhesion assay
The methods for the morphological experiments are referenced in previous studies [27] [28] [29] [30] with very small modifications. In this part, there are five groups: blank control group, empty viral particles control group, PARGshRNAi group, PARG-shRNAi þ LY group and positive control group. Cell adhesion assay was accomplished by using dyestuff Ci-I, Ci-O (Beyotime, Beijing, China) as described formerly with slight modification. Labeling CT26 cells: when CT26 cells reached 70% confluence, fresh medium that contained 20 mM Ci-O was added and the cells were put in the incubator for 20 min. Labeling platelets: Mixtures of venous blood from balb/c murine postcava with ACD anticoagulant (38 mM citric acid/75 mM trisodium citrate/100 mM dextrose) was centrifuged (1200 Â g,10 min) to obtain platelets. Di-I was added in PSG (5 mM Pipes, pH 6.8/145 mM NaCl/4 mM KCl/0.5 mM sodium phosphate/5.5 mM glucose/0.5% bovine serum albumin) of final concentration of 20 mM to label platelets. When the stained CT26 cells reached 60-70% confluence in six-well plates (3 Â 10 spectrophotometer (Bio-Tek, Winooski, VT, USA) was used for detecting the adhesion rate.
Western blot analysis
Phosphate-buffered saline was used to wash CT26 cells in culture flask and were collected by scraping into centrifugation tube. Protein was extracted and the concentration was measured by Bradford method, using a kit (SBS). Protein (18 mg per lane) was loaded onto 10% polyacrylamide gels (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), which were subject to electrophoresis, transferred to nitrocellulose membranes and the relevant proteins were blocked with 5% non-fat dried milk dissolved in tris-buffered saline tween. Primary antibodies against PARG, PARP-1, NF-kB, p-Akt, ICAM-1 and P-selectin (Abcam, Cambridge, UK) were incubated overnight at 4 1C. Secondary antibodies (peroxidase-conjugated goat or anti-rabbit immunoglobulin G) were added and incubated for 1 h at room temperature. The blots were then washed with tris-buffered saline tween. Finally, the blots were examined in a luminoscope (Bio-Rad, Hercules, CA) to measure enhanced chemiluminescence reagent (Pierce, Rockford, IL, USA) 600 ml totally; the optical density value was calculated using software (Quantity One; Bio-Rad).
RESULTS
Effect of lentiviral transfection on CT26 cells
Both real-time PCR and western blotting (Figure 1 ) results showed that the expression of PARG in the PARG-shRNAi group was clearly lower than that in the control groups (Po0.05) and that there was no distinction between the blank control group and the empty viral particles control group (P40.05).
PARG suppression suppresses the ability of CT26 cells to adhere to platelets in vitro In the adhesion assay (Figure 2 ), the adhesion of platelets to CT26 cells in PARG-shRNAi groups was diminished, when compared with blank control group (Po0.05). The adhesion was not obviously changed when transfected with empty viral particles control group, compared with blank control group (P40.05). The decrease in adhesion was statistically significant in the PARG-shRNAi þ LY group, when compared with PARG-shRNAi group (Po0.05).
Inhibition of PARP-1 depresses the expression of P-selectin and ICAM-1 on CT26 cells In this study, we examined the expression of P-selectin and ICAM-1 in protein level on CT26 cells by treating with 5-aminoisoquinolinone, as shown by western blot (Figure 3) . We found that the expression of P-selectin and ICAM-1 in CT26 cells was lower in the 5-aminoisoquinolinone-treated group than in the control group, indicating that inhibition of PARP-1 attenuated expression of P-selectin and ICAM-1 in CT26 cells. PARG silencing hinders adhesion of cell-platelet J Yan et al
Suppression of expression of PARG increases phosphorylation of Akt and decreases expression of NF-kB, PARP, ICAM-1 and P-selectin in CT26 cells
To determine the reaction between PARG and PARP-1, we analyzed PARP-1 protein expression by western blot. We observed that PARP-1 was more abundant in the empty-vector shRNA group than in the PARG-silenced group. Therefore, knockout of PARG indeed suppressed the expression of PARP-1 in CT26 cells ( Figure 5 ). Western blot was also performed to detect the effect of silencing of PARG expression and interdiction of PI3K/Akt pathway on expression of NF-kB, P-selectin and ICAM-1 in CT26 cells (Figures 4 and 5) . The results showed that expressions of PARG, PARP-1, NF-kB, P-selectin and ICAM-1 were reduced in the PARGshRNAi group compared with the blank control group. Simultaneously, p-Akt was upregulated (Po0.05). There were no evident changes when cells were transfected with empty viral particles compared with blank control group (P40.05). Expression of p-Akt was reduced, while expression of NF-kB, ICAM-1 and P-selectin was upregulated in the PARG-shRNAi þ LY group, when compared with PARG-shRNAi group (Po0.05; Figure 5 ). All these results indicated that suppression of expression of NF-kB, ICAM-1, P-selectin in PARG expression-silenced CT26 cells could be mediated, at least partially, by the PI3K/Akt pathway.
DISCUSSION
In this study, we have shown the following: (a) silencing of expression of PARG led to inhibition of adhesion of CT26 cells to platelets, whereas an inhibitor of p-Akt boosted adhesion of PARG-shRNAi CT26 cells to platelets; (b) an inhibitor of PARP-1 catalytic activity depressed the expression of P-selectin and ICAM-1 on CT26 cells; (c) silencing of the expression of PARG increased phosphorylation of Akt and decreased the expression of PARP-1, NF-kB, ICAM-1 and P-selectin in CT26 cell; and (d) P-Akt inhibitor intensified the expression of NF-kB, ICAM-1 and P-selectin on PARG-shRNAi CT26 cells accordingly. Taken together, these results show the effectiveness of knockout of PARG in inhibiting the adhesion of CT26 cells to platelets and its connection with PI3K/ Akt pathway.
In this study, we found that knockout of the PARG gene not only silenced PARG but also inhibited expression of PARP-1 in CT26 cells. We discovered the same phenomenon in human colon carcinoma cells (LoVo cells) in a previous study. 8 How to explain that knockout of PARG inhibited the expression of both PARG and PARP-1 in CT26 cells? We had previously proved that inhibition of PARG activity could result in reduction of expression of PARP-1 through inhibition of NF-kB in LoVo cells. 31 Similarly, Rapizzi et al. 32 demonstrated that inhibition of PARG restrained the activity of NF-kB. These evidences could explain the loss of expression of PARP-1 in PARG-silenced CT26 cells. Hence, we propose that PARG and PARP-1 cooperate with each other rather than indulge in mutual antagonism in CT26 cells. Besides, our results showed a significant rise of phosphorylation of Akt and suppression of expression of PARP-1 in PARG-shRNAi CT26 cells. This accords with the theory that was inhibition of PARP-1 could activate the PI3K/Akt pathway. [24] [25] [26] Namely, knockout of PARG inhibited expression of PARP-1, resulting in activation of Akt in CT26 cells.
Akt has been shown to be a classical upstream positive factor of activation of NF-kB signaling in various studies. Curiously, in our experiment, we found that expression of NF-kB was inhibited with high p-Akt in PARG-shRNAi CT26 cells, while it increased with depletion of p-Akt in PARG-shRNAi CT26 cells. This interesting outcome was probably due to knockout of PARG, although the mechanism of regulation of p-Akt on NF-kB in PARG-shRNAi CT26 cells is unclear. Studies by Veto et al. 33 and Bartha et al. 34 indicated that inhibition of PARP-1 suppressed c-Jun N-terminal kinase and p38 mitogen-activated protein kinase (MAPK) phosphorylation and increased the activation of the cytoprotective PI3K/Akt pathway. Similarly, Veres et al. 26 reported that inhibition of PARP-1 activated the PI3K/Akt pathway and downregulated extracellular signalregulated kinases 1 and 2 and p38 MAPK. In addition, they demonstrated that attenuation of NF-kB activation through inhibition of PARP-1, was mediated, at least in part, through the regulation of the PI3K/Akt pathway and MAP kinase cascades. These results explained that PI3K/Akt was not the only pathway involved in activation of NF-kB in CT26 cells in which expression of PARG had been silenced; at least, extracellular signal-regulated kinases 1 and 2 and p38 MAPK had some contribution as well. The same inhibition of NF-kB had been shown with inhibition of PARP-1 in our previous study. 35 Besides, Rane et al. 36 proved that downregulation of Akt activation during long-term hyperglycemia contributed to enhanced activation of p38 MAPK. Interestingly, in our recent study, we found that knockout of expression of PARG inhibited expression of PARP-1 and activity of NF-kB in LoVo cells, as well as restrained phosphorylation of p38 and extracellular signal-regulated kinase. 37 These studies collectively could explain the relationship between PI3K/Akt pathway and activation of NFkB in PARG-shRNAi CT26 cells. As Akt was neither the only cell signal effected by PARP-1 inhibition, nor the only upstream factor of NF-kB signaling, inhibition of PARP-1 probably downregulated NF-kB activation via a multi-pathway mechanism. Therefore, we speculated that inhibition of PARP-1 in PARG-shRNAi CT26 cells could activate p-Akt resulting in an increase of expression of NF-kB with downregulated extracellular signal-regulated kinase and p38 MAPK activation leading to decrease of NF-kB expression. On the other hand, activation of Akt could reduce phosphorylation of p38 MAPK, thus inhibiting further the expression of NF-kB. All in all, PARG-shRNAi CT26 cells may present low expression of NF-kB because inhibition of PARP-1 impacted several pathways, while PI3K/Akt pathway probably has crucial and diverse roles in the regulation of NF-kB. Further research is needed to examine this hypothesis.
High expressions of P-selectin and ICAM-1 were detected in CT26 cells, and the ligands of P-selectin and ICAM-1 (PSG-1 and LFA-1) were found on the surface of platelets. 10, 15 Thus, we concluded that adhesion of CT26 cells to platelets was mediated, at least partly, by combination of P-selectin and ICAM-1 on CT26 cells and their ligands on platelets. NF-kB, a transcription factor, regulates the amount of adhesion molecules, including P-selectin and ICAM-1, 22, 23 which make contribution to adhesion of CT26 cells to platelets. In our earlier study, we demonstrated that activation of NF-kB was downregulated when CT26 cells were treated with inhibitors of PARP-1, 35 while, in this research, according with our adhesion data, we found a remarkable reduction in the expression of P-selectin and ICAM-1 by both pharmacological inhibition of PARP-1 and by depletion of PARG. By contrast, low expression of PARP-1 and high expression of p-Akt were detected in CT26 cells in which expression of PARG was silenced. According to all these results, we deduce that PARGshRNA CT26 cells were weakly adhesive to platelets probably as a result of depression of NF-kB-regulated adhesion molecules, such as ICAM-1 and P-selectin, by restraining the PARP-1 and PI3K/Akt pathway involved in this interaction. In parallel, research by Cuzzocrea et al. 38 noted that reduction of PARG activity decreased ICAM-1 and P-selectin in mouse inflammatory bowel disease, which supported our finding from inflammatory pathologic processes. By contrast, increasing expression of NF-kB, P-selectin and ICAM-1 resulted from treated PARG-silenced CT26 cells, which had been treated with an inhibitor of p-Akt. Based on our results, we therefore speculated that one mechanism by which knockout of PARG decreased adhesion of tumor cells to platelets was due to inhibition of PARP-1 activity, which impacted several signal pathways. Thus, the PI3K/Akt pathway may interact with others, leading to diminution of the expression of NF-kB in total and, consequently, downregulation of NF-kB-dependent genes, such as P-selectin and ICAM-1.
In summary, we present experimental evidence which suggested that attenuation of adhesion of CT26 cells to platelets by silencing PARG could be mediated, at least in part, by inhibiting expression of P-selectin and ICAM-1. As for the mechanism, we proposed that knockout of PARG could activate Akt by inhibiting PARP-1 activity, leading to decreased expression of NF-kB, resulting in diminution of expression of P-selectin and ICAM-1. As PI3K/Akt is not the sole pathway in regulating NF-kB signaling, further studies are under way to sketch the whole picture of silencing of PARG affecting adhesivity of CT26 cells through other pathways.
Adhesion of tumor cells to platelets is the crux of formation of tumor emboli, which are the final consequences of hematogenous metastasis and the cause of death for most cancer patients. Our study elucidated that the mechanism of adhesion of colorectal cancer cells to platelets was complicated and related to multiple pathways. In addition, we propounded a further idea of exploring role of PARG in adhesion of tumor cells and platelets. With deeper studies done, more and more target genes would be discovered for preventing or treating metastasis of colorectal cancer. PARG is probably a potential target to inhibit formation of tumor emboli, according to our research.
